Prospects for the future in the management of carcinoma of the breast: The biological fall out from clinical trials.
1984

Future Management of Breast Cancer

Sample size: 1300 Editorial Evidence: moderate

Author Information

Author(s): M. Baum

Primary Institution: Kings College Hospital, London

Hypothesis

How can data from clinical trials advance our understanding of breast cancer treatment?

Conclusion

Data from clinical trials suggest that the lymph node status is more of an expression of prognosis rather than a determinant.

Supporting Evidence

  • Large clinical trials can reveal important differences in treatment outcomes.
  • Tamoxifen has shown a prolonged disease-free interval in treated groups.
  • Node-positive patients are often predetermined to have worse outcomes.

Takeaway

This article talks about how big studies on breast cancer can help us understand better ways to treat it, especially with new medicines like tamoxifen.

Methodology

The article reviews past clinical trials and discusses their implications for future research and treatment strategies.

Potential Biases

Potential bias in interpreting results from historical controls versus randomized trials.

Limitations

The article does not provide new experimental data but rather discusses existing studies and their interpretations.

Participant Demographics

The study involved premenopausal and postmenopausal women with node-positive and negative breast cancer.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication